Following the meta-analysis, Pr Vermassen talks about his current practice and best options to treat challenging lesions

Following the meta-analysis, Pr. Vermassen talks about his current practice and best options to treat challenging lesions. 


Boston Scientific’s Drug-Eluting Technologies are designed to optimize drug transfer to bring patients the best clinical outcomes with the lowest possible drug dose. 


Proven platform combined with advanced technology to target drug delivery to the vessel.



Eluvia and Ranger are the lowest drug dose density devices among all peripheral paclitaxel-based technologies.



Data from Eluvia, Lutonix, Stellarex, Ranger, Zilver PTX and IN.PACT DFUs.



The only company bringing you Level 1 Head-to-Head Trials, providing safety and efficacy evidence in both low dose DES and DCB.


Eluvia has demonstrated consistent results and proven benefits in patients at high risk of restenosis.

89.2% Primary Patency: IMPERIAL Severe / Moderate Calcium Subgroup Analysis

IMPERIAL Severe/Moderate Calcium Subgroup Analysis

Eluvia demonstrated a 89.2% primary patency in severe and moderately calcified lesions.1,2

70% Reduction in TLR vs. Control: IMPERIAL Diabetic Subgroup Analysis

IMPERIAL Diabetic Subgroup Analysis

Eluvia demonstrated a statistically significant reduction in Target Lesion Revascularization (TLR) of greater than 70% in diabetic patients.

87.9% Primary Patency: IMPERIAL Long Lesion Substudy

IMPERIAL Long Lesion Sub-Study

Eluvia demonstrated a 87.9% primary patency in the IMPERIAL Long Lesion Sub-Study.1

Sign Up Today

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore Resources

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

1. Kaplan Meier Estimate; Primary patency as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤ 2.4 at the 12-month follow-up visit, in the absence of clinically-driven TLR or bypass of the target lesion.

2. Versus 87.0% primary patency in the none/mild calcium arm of the IMPERIAL Calcium Subgroup.